The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...

The future of skin cancer treatment looks even more promising. Advances in artificial intelligence (AI) are revolutionizing ...

ImmunityBio has a promising cancer treatment, Anktiva. We warn of financial risks and lack of transparency for retail investors. See more on IBRX stock here.

Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.

Shares of Replimune Group, Inc. (NASDAQ: NASDAQ:REPL) surged 17% following the announcement that the U.S. Food and Drug ...

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...

(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...

Replimune Group Inc (NASDAQ: NASDAQ:REPL), a biotech firm focused on oncolytic immunotherapies, announced today that its Biologics License Application (BLA) for RP1 in combination with nivolumab has ...

Group announced that the U.S. Food and Drug Administration, FDA, has accepted the Biologics License Application, BLA, for RP1 ...

Decades since Elvis Presley dominated the music charts, children are among those celebrating the King of Rock and Roll. The Parkes Elvis Festival has returned for another year and there are dozens ...

Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer ...

Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...